Aimmune therapeutics, inc. (AIMT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-280,663

-248,497

-238,597

-225,844

-215,518

-210,752

-194,920

-175,010

-154,955

-131,325

-115,235

-105,529

-91,171

-80,824

-71,756

-58,661

-47,898

-35,816

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

1,600

1,418

1,351

1,212

1,000

844

664

553

534

448

342

229

115

0

0

0

Stock-based compensation expense

35,467

32,929

32,655

32,956

32,890

32,732

29,511

25,208

20,733

16,719

15,419

14,828

13,703

12,641

12,499

10,773

8,662

6,157

0

0

0

Non-cash interest expense

5,784

4,626

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium on investment securities

1,095

1,631

1,856

1,755

1,403

886

495

114

-246

-511

-648

-793

-868

-919

0

0

0

-

-

-

-

Research and development expenses recognized from issuance of common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Trade receivables, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-4,884

-3,888

-1,447

-792

526

1,995

188

1,603

1,506

1,435

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Accounts payable

4,446

6,200

-1,124

5,595

5,064

2,688

7,574

3,991

1,635

2,315

2,273

534

-667

-994

143

596

495

1,072

0

0

0

Accrued liabilities

3,435

2,039

5,635

-1,841

1,409

7,412

6,697

12,509

15,486

11,557

6,599

10,903

5,045

6,803

8,400

1,636

2,937

1,859

0

0

0

Other liabilities

1,417

952

611

421

-82

75

932

1,132

918

1,087

452

185

111

340

0

0

0

-

-

-

-

Net cash used in operating activities

-221,371

-195,400

-194,350

-184,811

-175,193

-169,128

-149,505

-132,570

-116,265

-99,605

-90,290

-76,646

-68,135

-56,614

-52,594

-50,216

-43,280

-35,690

0

0

0

Purchase of property and equipment

6,994

8,047

8,214

8,037

8,409

9,420

9,473

9,817

7,908

6,425

6,192

5,972

7,449

7,665

7,342

5,656

2,780

1,708

0

0

0

Purchase of investments

113,214

166,321

208,406

235,065

282,583

261,293

212,428

187,883

138,389

129,534

203,032

190,747

189,533

197,178

0

0

0

-

-

-

-

Maturities of investments

256,499

286,267

263,705

213,231

191,309

174,703

174,239

187,139

196,314

178,521

146,430

134,256

129,870

160,947

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

136,291

111,899

47,085

-29,871

-99,683

-96,010

-47,662

-10,561

50,017

42,562

-62,794

-62,463

-67,112

-43,896

16,147

-103,716

-125,279

-125,229

0

0

0

Cash flows from financing activities:
Borrowings under debt agreement

85,000

40,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issuance costs

-

3,856

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of preferred and common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from underwritten public offering, net of offering costs

-

-

-

-

-

288,435

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash proceeds from exercise of stock options

19,152

20,406

12,262

11,612

11,984

10,727

0

0

0

-

4,994

4,130

3,916

2,843

695

305

150

303

0

0

0

Tax withholdings related to net share settlements of restricted stock units

1,609

672

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

302,450

55,878

145,734

145,084

146,610

299,162

201,766

200,837

196,858

6,520

149,994

149,130

148,916

147,843

697

169,860

168,291

235,327

0

0

0

Effects of changes in foreign exchange rates

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

217,360

-27,631

-1,576

-69,593

-128,266

34,024

4,599

57,706

130,610

-50,523

-3,090

10,021

13,669

47,333

-35,750

15,928

-268

74,408

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued liabilities

117

1,048

1,806

2,661

564

1,301

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Receivable for underwritten public offering

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Receivable for stock option exercises

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-